Peter Kiener - Jan 2, 2024 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
Director
Signature
/s/ Peter Kiener by Colin Sandercock, attorney-in-fact
Stock symbol
CUE
Transactions as of
Jan 2, 2024
Transactions value $
$0
Form type
4
Date filed
1/4/2024, 04:02 PM
Previous filing
Jun 23, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Stock Option (right to buy) Award $0 +24.4K $0.00 24.4K Jan 2, 2024 Common Stock 24.4K $2.78 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy.
F2 This option was granted on January 2, 2024. The shares underlying the option are scheduled to vest in full on the anniversary date of the grant date.